logo-loader
RNS
Advanced Oncotherapy PLC

Advanced Oncotherapy - Update on Financial Results

RNS Number : 2331O
Advanced Oncotherapy PLC
29 September 2023
 

29 September 2023

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy", "AVO" or the "Company")

 

Update on publication of annual report and interim results

 

Further to the announcement on 30 June 2023, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, provides an update on the publication of the Company's annual report and accounts for the year ended 31 December 2022 (the "2022 Annual Report") and the unaudited interim results for the six months ended 30 June 2023 (the "2023 Interim Results", together with the 2022 Annual Report, the "Results").

 

On 30 June 2023, the Company announced that its shares would be suspended from trading on AIM pending clarification of its financial position and, in light of this, that the Company would not be in a position to publish its 2022 Annual Report by 30 June 2023, as stipulated by Rule 19 of the AIM Rules for Companies ("AIM Rules").

 

The 2023 Interim Results are contingent on the finalisation and publication of the 2022 Annual Report which the Company will not be able to publish by 30 September 2023. Accordingly, the Company will not be able to publish its 2023 Interim Results by 30 September 2023, as stipulated by Rule 18 of the AIM Rules.

 

The Company's shares remain suspended from trading on AIM.

 

Further to the announcement released by the Company on 17 July 2023 (the "July Announcement") regarding its prospective recapitalisation and funding plan, the Company continues to work on its recapitalisation plan and with a view to further funding being secured, including the bridge financing referred to in the July Announcement which is required to alleviate the Company's immediate financing needs. Discussions on the bridge financing are at an advanced stage however as at the date of this announcement the Company has not entered into any agreements on the bridge financing with investors nor have any funds been received from investors.  

 

The Company intends to provide a more detailed update on the prospective recapitalisation and funding plan in early October 2023.

 

Further announcements on the Results will be made at the appropriate time.

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




WH Ireland Limited (Financial adviser)

Tel: +44 (0) 20 7220 1666

Antonio Bossi / James Bavister

AVOPLC@whirelandcm.com



Allenby Capital Limited (Nomad and Joint Broker)


Nick Athanas / Piers Shimwell (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Corporate Broking)

Tel: +44 (0) 20 3328 5656



SI Capital Ltd (Joint Broker)


Nick Emerson

Tel: +44 (0) 1483 413 500

Jon Levinson

Tel: +44 (0) 20 3871 4066



 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy Plc, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy Plc will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy Plc continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPPUPUBUPWGAB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read